Literature DB >> 7356688

Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma.

C F Scott, R W Colman.   

Abstract

Plasma from individuals with high molecular weight (HMW) kininogen deficiency has been reported to be deficient in prekallikrein as measured by radial immunodiffusion, prekallikrein coagulant activity, and/or kaolin-activated arginine esterase activity. The discovery that prekallikrein and HMW kininogen circulate as a complex in plasma led us to reevaluate the antigenic and functional properties of prekallikrein in HMW kininogen-deficient plasma as well as in normal plasma. The low prekallikrein antigen level in an individual with HMW kininogen deficiency was corrected to the normal range (80-95%) by the addition of 0.2 U/ml of purified HMW kininogen. A similar increase in apparent prekallikrein antigen was observed when purified prekallikrein and HMW kininogen were combined. The correction of the apparent prekallikrein defect in this HMW kininogen-deficient plasma coincided with the formation of a prekallikrein-HMW kininogen complex as demonstrated by immunoelectrophoresis. Similar findings were demonstrated with purified prekallikrein and HMW kininogen by immunoelectrophoresis as well as crossed immunoelectrophoresis. The coagulant activity in HMW kininogen-deficient plasma was increased in a dose-dependent manner by the addition of HMW kininogen, reaching 85% of normal level at a concentration of 0.2 U/ml. Kaolin-activated arginine esterase activity (kallikrein) in HMW kininogen-deficient plasma was fully corrected when HMW kininogen was added to the deficient plasma after depletion of kallikrein inhibitors. The functional and antigenic concentration of prekallikrein in plasma from four other HMW kininogen-deficient individuals was similarly corrected to normal after adding HMW kininogen. Addition of HMW kininogen increased the apparent prekallikrein activity in native normal plasma (as measured by esterase activity) but not in normal plasma in which inhibitors were inactivated. The apparent prekallikrein antigen concentration (as measured by radial immunodiffusion or electroimmunodiffusion) increased upon addition of HMW kininogen. Immunoelectrophoresis as well as gel filtration of normal plasma revealed the presence of free prekallikrein (17-38% of the total) in addition to the HMW kininogen-prekallikrein complex previously reported. This study emphasizes the influence of HMW kininogen on both functional and immunologic determinations of prekallikrein.

Mesh:

Substances:

Year:  1980        PMID: 7356688      PMCID: PMC371379          DOI: 10.1172/JCI109684

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.

Authors:  R R PROCTOR; S I RAPAPORT
Journal:  Am J Clin Pathol       Date:  1961-09       Impact factor: 2.493

2.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

3.  Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein.

Authors:  R W Colman; L Mattler; S Sherry
Journal:  J Clin Invest       Date:  1969-01       Impact factor: 14.808

4.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

7.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.

Authors:  R W Colman; A Bagdasarian; R C Talamo; C F Scott; M Seavey; J A Guimaraes; J V Pierce; A P Kaplan
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

8.  Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis.

Authors:  V H Donaldson; H I Glueck; M A Miller; H Z Movat; F Habal
Journal:  J Lab Clin Med       Date:  1976-02

9.  Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma.

Authors:  R J Mandle; R W Colman; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

10.  Plasma kallikrein activation and inhibition during typhoid fever.

Authors:  R W Colman; R Edelman; C F Scott; R H Gilman
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

View more
  15 in total

Review 1.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 2.  Surface-mediated defense reactions. The plasma contact activation system.

Authors:  R W Colman
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

3.  Human neutrophils contain and bind high molecular weight kininogen.

Authors:  E J Gustafson; A H Schmaier; Y T Wachtfogel; N Kaufman; U Kucich; R W Colman
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 4.  Structure and function of factor XI.

Authors:  Jonas Emsley; Paul A McEwan; David Gailani
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.

Authors:  Evi X Stavrou; Chao Fang; Alona Merkulova; Omar Alhalabi; Nadja Grobe; Silvio Antoniak; Nigel Mackman; Alvin H Schmaier
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

6.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

7.  Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.

Authors:  C F Scott; M Schapira; H L James; A B Cohen; R W Colman
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

8.  High-molecular weight kininogen. A secreted platelet protein.

Authors:  A H Schmaier; A Zuckerberg; C Silverman; J Kuchibhotla; G P Tuszynski; R W Colman
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

Review 9.  Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema.

Authors:  Steven de Maat; Kusumam Joseph; Coen Maas; Allen P Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-06       Impact factor: 8.667

10.  Structural requirements for the procoagulant activity of nucleic acids.

Authors:  Julia Gansler; Miriam Jaax; Silke Leiting; Bettina Appel; Andreas Greinacher; Silvia Fischer; Klaus T Preissner
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.